India tests samples of cough syrup linked to deaths of children in Gambia

NEW DELHI: India said it is testing samples of cough syrups produced by local manufacturer Maiden Pharmaceuticals for export after the World Health Organization said its products were linked to the deaths of dozens of children in Gambia. The deaths of 66 children in the West African country could deal a major blow to India's image as a "pharmacy of the world". The WHO this week said laboratory analysis of four Maiden products - Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup - had confirmed "unacceptable" amounts of diethylene glycol and ethylene glycol, which can be toxic and lead to acute kidney injury. Diethylene glycol and ethylene glycol are used in antifreeze and brake fluids and other industrial applications but also as a cheaper alternative in some pharmaceutical products to glycerine, a solvent or thickening agent in many cough syrups. India's health ministry said samples of all four products that had been exported to Gambia had been sent for testing to a federal laboratory and the results would "guide the further course of action as well as bring clarity on the inputs received/to be received from WHO." It asked the WHO to share its report on the "establishment of causal relation to death with the medical products in question." WHO spokesperson Margaret Harris did not directly reply to a Reuters query on when the report might be shared with the health ministry. She said, however, that information from Maiden and India's director of the Central Drugs and Standard Control Organisation indicated that authorities had visited the company's factories "to investigate this specific incident and WHO awaits the findings". Anil Vij, the health minister of Haryana state where Maiden has its factories, warned of "strict action if anything is found wrong" after the tests. WHO Director-General Tedros Adhanom Ghebreyesus told reporters on Wednesday that the U.N. agency was investigating the deaths from acute kidney injuries with India's drug regulator and the drug maker. The agency informed the Drugs Controller General of India of the deaths late last month after which the regulator launched an investigation with state authorities in tandem with the WHO. Naresh Kumar Goyal, a Maiden director, told Reuters, however, that the company had heard about the deaths only on Thursday morning and was trying to find out details. "We are trying to find out the situation because it cropped up only today," he said by phone. "We are trying to find out with the buyer and all that what has happened exactly. We are not selling anything in India." He declined to speak further. Maiden, which launched its operations in November 1990, manufactured and exported the syrup only to Gambia, the Indian health ministry said. Maiden on its website says it has two manufacturing plants, in Kundli and Panipat, both near New Delhi in Haryana, and has recently set up another one. Maiden has an annual production capacity of 2.2 million syrup bottles, 600 million capsules, 18 million injections, 300,000 ointment tubes and 1.2 billion tablets. Maiden on its website says it sells its products at home and exports to countries in Asia, Africa and Latin America, although Goyal said they were not currently selling in India. The health ministry said importing countries typically test such products before allowing their use. (Reporting by Krishna N. Das in New Delhi; Writing by Shilpa Jamkhandikar; Editing by Robert Birsel, Mark Porter and Edwina Gibbs)

India tests samples of cough syrup linked to deaths of children in Gambia

DISCOVER MORE

Ramadan in UAE: Police warn residents against helping beggars; launch campaigns to curb the crime

Rent scam in Dubai: Man jailed for taking deposit, cheques for villa he didn't own

Bullying, data leakage: UAE cybersecurity expert warns of increase in crimes while working, learning remotely

General Directorate of Narcotics Control thwarts attempt to smuggle more than 4.6mln Amphetamine pills

Cybercriminals' crypto platform ChipMixer seized in international operation

Dubai Customs handles over 5mln bags at Airport Terminal 2

Are New York prosecutors about to charge Trump?

Saudi: MHRSD penalizes recruitment office for harboring female workers illegally

Can GCC banks manage contagion risk from Silicon Valley Bank collapse?

Saudi National Bank says no impact on growth plans from Credit Suisse

SNB offers $100bln to help UBS Group take over Credit Suisse

Oman reveals list of 103 countries whose citizens can visit visa free

Dubai is proactively developing plans to accelerate digital growth - Sheikh Hamdan

Indian cenbank fines RBL Bank for non-compliance with rules on loan recovery agents

India's Supreme Court asks SEBI to refund to NSE

India's top court rejects govt plea seeking more compensation for Bhopal gas disaster victims

India's top court refers same-sex marriage recognition case to 5-judge bench

India investigating corruption allegations against Red Cross branches

LATEST VIDEO

VIDEO: Saudi crown prince launches new national airline

ZAWYA COVERAGE

ACWA Power CEO Paddy Padmanathan retires after 18 years of service

Dubai’s DEWA, JPMorgan tackle ways to cooperate in green, sustainable financing

Saudi ACWA Power signs deals to invest $2.5bln in green projects in Uzbekistan

Healthcare expenditure in GCC to reach $135.5bln in 2027

Amazon to cut 9,000 jobs in second round of layoffs

India's strong corporate debt profile key to macroeconomic stability

Somalia's drought killed 43,000 last year, half under five

Mideast Stocks: Most Gulf bourses end lower as oil prices drop; Egypt rises

UAE President, Romanian President review bilateral relations, regional issues

THE BRI REPORT

China is reshaping the Belt and Road Initiative ahead of a post-pandemic era

DISCOVER MORE

LATEST VIDEO

ZAWYA NEWSLETTERS

ZAWYA COVERAGE